Competitive Intelligence

Diverse approaches in immuno-oncology

A fascinating range of insights into the ways in which the immune system can be harnessed to fight cancer was provided by Global Engage’s Immuno-Oncology Research & Technology Series meeting this month in London. The conference comprised five concurrent tracks covering cutting-edge developments in fields such as cell therapies, novel antibodies and neoantigens. Some of […]

Busy biopharma M&A activity closed out 2018

During the fourth quarter of 2018, Cortellis Deals Intelligence registered 140 new mergers and acquisitions (M&A) with a total disclosed deal value of $33.1 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 153 and $20.3 billion in the third quarter and 151 and $100.7 billion in […]

Biopharma licensing finished with a strong Q4

During the fourth quarter of 2018, Cortellis Competitive Intelligence   registered 1,073 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $46.1 billion as part of its ongoing coverage of licensing activity in the life sciences sector. The totals represented a 7.4% increase from 994 and a 41.4% increase from $27 billion […]

Licensing deals driving the life sciences industry in Q3: notes and trends

During the third quarter of 2018, Cortellis Competitive Intelligence registered 984 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $26 billion as part of its ongoing coverage of licensing activity in the life sciences sector compared to 1,060 and $20.8 billion in the second quarter and 1,158 and $33.6 billion […]

Q3 M&A deals driving the life sciences industry

Trends in M&A volume and deal value During the third quarter of 2018, Cortellis Deals Intelligence registered 131 new mergers and acquisitions (M&A) with a total disclosed deal value of $16 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 113 and $104.6 billion in the second […]

Predictive analytics yield smarter pharma portfolio decisions

Collecting competitive data isn’t the problem; most biopharma companies are drowning in it. But making sense of the data, using it to predict likely shifts in the competitive landscape and drive decisions can be a challenge. While forecasting drug timelines and success rates are critical to inform investment and R&D decisions, the standard approach has […]

Generics companies, responding to tough times, steer towards higher-risk portfolio strategies

These are tough times financially and strategically for many generics companies, particularly in the U.S., the world’s largest pharmaceutical market. Manufacturers are experiencing falling net prices driven by customer consolidation and increasing competition, coupled with a lack of operational flexibility and a landscape of new product opportunities significantly different from those of the past. Additionally, […]

PolyPEPI-1018: A hopeful advance in the fight against cancer – and a milestone for us

Meet PolyPEPI-1018, a cancer vaccine being developed by Treos Bio Ltd. for the treatment of metastatic colorectal cancer. PolyPEPI-1018 contains six synthetic polypeptides that are precisely selected to induce immune cell responses against 12 epitopes from seven cancer testis antigens (CTAs) most frequently expressed in colorectal cancers. These polypeptides are optimized with the PEPI biomarker […]

Life sciences M&A deals in the fourth quarter of 2017: updates and trends

During the fourth quarter of 2017, Cortellis Deals Intelligence registered 122 new mergers and acquisitions (M&A) with a total disclosed deal value of $92.3 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 121 and $30.1 billion in the third quarter and 111 and $22 billion in […]

Life sciences licensing deals in the fourth quarter of 2017: updates and trends

During the fourth quarter of 2017, Cortellis Competitive Intelligence registered 1,107 new deals (excluding mergers & acquisitions) as part of its ongoing coverage of licensing activity in the life sciences sector compared to 1,043 in the third quarter and 1,035 in the fourth quarter of 2016.   High-value deals: worth $0.5 billion or more We […]